LenaRIC: Phase II study of the adjunctive use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma

Trial Overview and Summary

Allogeneic SCT remains the only curative option for Multiple Myeloma. However, conventional transplants remain associated with a substantial transplant related mortality which compromises effectiveness in younger patients and precludes their use entirely in patients over the age of 55 years. The tolerability and remarkable activity of lenalidomide against myeloma makes it an excellent candidate to be used in an adjunctive role early after a reduced intensity regimen transplant prior to later institution of DLI, to suppress the growth and rapid recovery of a residual myeloma cell population.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Dr Mark Cook
Sponsor: University Hospitals Birmingham NHS Foundation Trust
Funders: CRUK Feasibility Study Committee. Educational grant provided by Celgene Ltd
Disease Site: Multiple myeloma (Leukaemia)
Trial Type: Clinical Trial of an Investigational Medicinal Product
Status: Closed
UKCRN Study ID: 7268
Open to new sites? No
Recruitment start date: 31/05/2011
Anticipated Recruitment end date: N/A- closed to recruitment
CRCTU Trial Management Team: Haematology
Trial E-mail Address: LenaRIC@trials.bham.ac.uk

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their healthcare professional or refer to CancerHelp website [opens new page].


More information

CancerHelp (Cancer Research UK) - LenaRIC trial [opens new page]